Clinical trial
Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO)
NCT05263206 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO)
- Lead sponsor
- Sanofi
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- February 15, 2022
- Completion date
- August 25, 2027
- Enrollment
- 284 (estimated)
- Sites
- 93
Conditions
As the registry lists them; a condition with its own page is linked.